Chemoresponse assay for evaluating response to sunitinib in primary cultures of breast cancer

Cancer Biology and Therapy

Volumn 11, Issue 12, 2011, Pages 1059-1064

  Suchy, Sarah L ^a   Hancher, Lauren M ^a   Wang, Dakun ^a   Ervin Jr , Paul R ^a   Brower, Stacey L ^a  

^a Precision Therapeutics Inc   (United States)

Author keywords

Breast cancer; ChemoFx ; Chemoresponse; Individualized therapeutic response; Sunitinib

Indexed keywords

SUNITINIB;

ARTICLE; ASSAY; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CHEMORESPONSE ASSAY; CLINICAL ARTICLE; CLINICAL DECISION MAKING; DRUG RESPONSE; EX VIVO STUDY; HUMAN; HUMAN CELL; KIDNEY CELL; REFERENCE VALUE; REPRODUCIBILITY; SENSITIVITY ANALYSIS; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INDOLES; PYRROLES; QUALITY CONTROL; REFERENCE STANDARDS;

EID: 79958826653     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.11.12.15710     Document Type: Article

References (59)

1. American Cancer Society. Breast Cancer Facts & Figures 2009-2010. Atlanta: American Cancer Society, Inc.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-717.
3. Sledge GW Jr, Jotwani AC, Mina L. Targeted therapies in early-stage breast cancer: achievements and promises. Surg Oncol Clin N Am 2010; 19:669-79.
4. Hussain SA, Palmer DH, Spooner D, Rea DW. Molecularly targeted therapeutics for breast cancer. BioDrugs 2007; 21:215-24. (Pubitemid 47104977)
5. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007; 608:1-22.
6. Morgan G, Ward R, Barton M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol) 2004; 16:549-60. (Pubitemid 39517664)
7. Nagashima T, Sakakibara M, Sangai T, Kazama T, Nakatani Y, Miyazaki M. Tumor reduction rate predicts early recurrence in patients with breast cancer failing to achieve complete response to primary chemotherapy. Breast Cancer 2010; 17:125-30.
8. Clarke M. Meta-analyses of adjuvant therapies for women with early breast cancer: the early breast cancer trialists' collaborative group overview. Ann Oncol 2006; 17:59-62.
9. Anderson SJ, Wapnir I, Dignam JJ, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol 2009; 27:2466-73.
10. Mechera R, Viehl CT, Oertli D. Factors predicting inbreast tumor recurrence after breast-conserving surgery. Breast Cancer Res Treat 2009; 116:171-7.
11. Workman P, de Bono J. Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine. Curr Opin Pharmacol 2008; 8:359-62.
12. Allgayer H, Fulda S. An introduction to molecular targeted therapy of cancer. Adv Med Sci 2008; 53:130-8.
13. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010; 66:357-71.
14. Papaetis GS, Syrigos KN. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs 2009; 23:377-89.
15. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305:399-401. (Pubitemid 38938156)
16. Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, et al. Molecular target modulation, imaging and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 2009; 15:5902-9.
17. Janeway KA, Albritton KH, Van Den Abbeele AD, D'Amato GZ, Pedrazzoli P, et al. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer 2009; 52:767-71.
18. Yasui H, Imai K. Novel molecular-targeted therapeutics for the treatment of cancer. Anticancer Agents Med Chem 2008; 8:470-80.
19. Pfizer. SUTENT®; (sunitinib malate) for Treatment of mRCC and GIST. Pfizer for Oncology Professionals. Available at: http://www.pfizeroncology.com/ sites/pop/pages/sutent.aspx?tab=Indication
20. Grimaldi AM, Guida T, D'Attino R, Perrotta E, Otero M, Masala A, et al. Sunitinib: bridging present and future cancer treatment. Ann Oncol 2007; 18:31-4.
21. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25:884-96. (Pubitemid 350002890)
22. Pawson T. Regulation and targets of receptor tyrosine kinases. Eur J Cancer 2002; 38:3-10.
23. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2:471-8.
24. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003; 2:1011-21.
25. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-37.
26. Palmu S, Soderstrom KO, Quazi K, Isola J, Salminen E. Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer. Anticancer Res 2002; 22:411-4. (Pubitemid 34475331)
27. Kranz A, Mattfeldt T, Waltenberger J. Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 1999; 84:293-8. (Pubitemid 29256757)
28. Heng DY, Kollmannsberger C. Sunitinib. Recent Results Cancer Res 2010; 184:71-82.
29. Gan HK, Seruga B, Knox JJ. Sunitinib in solid tumors. Expert Opin Investig Drugs 2009; 18:821-34.
30. Mena AC, Pulido EG, Guillen-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs 2010; 21:3-11.
31. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26:1810-6.
32. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20:757-66.
33. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, et al. Efficacy, safety and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27:3027-35.
34. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009; 27:3154-60.
35. Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 2007; 18:3-10.
36. Motzer RJ, Hoosen S, Bello CL, Christensen JG. Sunitinib malate for the treatment of solid tumours: a review of current clinical data. Expert Opin Investig Drugs 2006; 15:553-61.
37. Fratto ME, Imperatori M, Vincenzi B, Tomao F, Santini D, Tonini G. New perspectives: role of Sunitinib in Breast Cancer. Clin Ter 2010; 161:475-82.
38. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995; 26:86-91.
39. Coltrera MD, Wang J, Porter PL, Gown AM. Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res 1995; 55:2703-8.
40. Manders P, Beex LV, Tjan-Heijnen VC, Geurts-Moespot J, Van Tienoven TH, Foekens JA, et al. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer 2002; 87:772-8. (Pubitemid 35178755)
41. Shirakawa K, Kobayashi H, Sobajima J, Hashimoto D, Shimizu A, Wakasugi H. Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model. Breast Cancer Res 2003; 5:136-9. (Pubitemid 36519406)
42. Kozloff M, Chuang E, Starr A, Gowland PA, Cataruozolo PE, Collier M, et al. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 2010; 21:1436-41.
43. Alvarez RH. Present and future evolution of advanced breast cancer therapy. Breast Cancer Res 2010; 12:1.
44. Peters D, Freund J, Ochs RL. Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer Ther 2005; 4:1605-16. (Pubitemid 41556444)
45. Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, Hosford S, et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 2006; 16:194-201.
46. Herzog TJ, Krivak TC, Fader AN, Coleman RL. Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer. Am J Obstet Gynecol 2010; 203:1-6.
47. Mi Z, Holmes FA, Hellerstedt B, Pippen J, Collea R, Backner A, et al. Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients. Anticancer Res 2008; 28:1733-40. (Pubitemid 351892877)
48. Frey K, Schliemann C, Schwager K, Giavazzi R, Johannsen M, Neri D. The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma. J Urol 2010; 184:2540-8.
49. Bhatt RS, Wang X, Zhang L, Collins MP, Signoretti S, Alsop DC, et al. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther 2010; 9:2793-802.
50. Roukos DH. Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 2009; 9:217-21.
51. Guevremont C, Alasker A, Karakiewicz PI. Management of sorafenib, sunitinib and temsirolimus toxicity in metastatic renal cell carcinoma. Curr Opin Support Palliat Care 2009; 3:170-9.
52. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, et al. Toxicities associated with the administration of sorafenib, sunitinib and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008; 53:917-30.
53. Cella D, Michaelson MD, Bushmakin AG, Cappelleri JC, Charbonneau C, Kim ST, et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs. interferon-alpha in a phase III trial: final results and geographical analysis. Br J Cancer 2010; 102:658-64.
54. Trippoli S, Messori A. Cost effectiveness of sunitinib. J Clin Oncol 2008; 26:5829.
55. Trippoli S, Messori A. Cost-effectiveness analyses of statistically ineffective treatments. Jama 1998; 280:1992-3. (Pubitemid 28562674)
56. Messori A, Santarlasci B, Trippoli S, Vaiani M, Vacca F, Brutti MC. Clinical-economic appropriateness of drug treatments: designing a method that combines evidence-based information and cost assessments to construct league tables accounting for the potential number of patients. Expert Opin Pharmacother 2004; 5:2381-9. (Pubitemid 39489990)
57. Messori A, Trippoli S, Vaiani M. Efficacy, safety and cost of new anticancer drugs. Price needs to be evaluated against effectiveness. Bmj 2002; 325:1302.
58. Heinzman JM, Rice SD, Corkan LA. Robotic liquid handlers and semiautomated cell quantification systems increase consistency and reproducibility in high-throughput, cell-based assay. JALA 2010; 15:7-14.
59. Rice SD, Heinzman JM, Brower SL, Ervin PR, Song N, Shen K, et al. Analysis of chemotherapeutic response heterogeneity and drug clustering based on mechanism of action using an in vitro assay. Anticancer Res 2010; 30:2805-11.